Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools

Transfusion

Volumn 48, Issue 5, 2008, Pages 822-826

  Nübling, C Micha ^a   Unkelbach, Uwe ^a   Chudy, Michael ^a   Seitz, Rainer ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VIRUS RNA;

ARTICLE; AUTOMATION; BLOOD TRANSFUSION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EUROPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID ANALYSIS; PLASMA; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; SAFETY; VIRAL CONTAMINATION; VIRUS DIAGNOSIS; VIRUS GENOME; VIRUS INACTIVATION; VIRUS LOAD;

BLOOD BANKS; BLOOD DONORS; DNA, VIRAL; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PLASMA; RNA, VIRAL; VIREMIA; VIRUS DISEASES;

EID: 42949106920     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01612.x     Document Type: Article

References (14)

1. Nübling CM, Chudy M, Löwer J. Virus testing of plasma pools and blood products by nucleic acid amplification. Hämostaseologie 1996 16 : 274 6.
2. Outbreak of hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-June 1994. MMWR 1994 43 : 505 9.
3. Committee for Proprietary Medicinal Products (CPMP). The introduction of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus RNA in plasma pools (CPMP/BWP/390/97). Addendum to note for guidance on plasma derived products (CPMP/BWP/269/95). London, 24.3.1998.
4. Monograph on "human plasma for fractionation." European Pharmacopeia 2007 5. 6 : 4603 4.
5. Monographs on "Human anti-D immunoglobulin" and on human anti-D immunoglobulin for intravenous administration. European Pharmacopeia 2007 5. 6 : 4595 6.
6. Monograph on "human plasma (pooled and treated for virus inactivation)." European Pharmacopeia 2007 5. 6 : 4604 5.
7. Nübling CM, Willkommen H, Löwer J. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995 345 : 1173 4.
8. Glynn SA, Kleinman SH, Schreiber GB, Busch MP, Wright DJ, Smith JW, Nass CC, Williams AE. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000 284 : 229 35.
9. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996 334 : 1685 90.
10. Busch MP. HIV, HBV and HCV: new developments related to transfusion safety. Vox Sang 2000 78 : 253 6.
11. Nübling CM, Unger G, Chudy M, Raia S, Löwer J. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 2002 42 : 1037 45.
12. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute infection. Transfusion 2003 43 : 788 98.
13. Margaritis AR, Brown SM, Seed CR, Kiely P, D'Agostino B, Keller AJ. Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA. Transfusion 2007 47 : 1783 93.
14. Nübling CM, Chudy M, Löwer J. Validation of HCV-NAT assays and experience with NAT application for blood screening in Germany. Biologicals 1999 27 : 291 4.